Back to top
more

OptimizeRx (OPRX)

(Delayed Data from NSDQ)

$10.12 USD

10.12
468,599

+1.32 (15.00%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $10.12 0.00 (0.00%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 252)

Industry: Computer - Software

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)

by Zacks Equity Research

OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)

by Zacks Equity Research

OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Bruker (BRKR) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Bruker (BRKR) delivered earnings and revenue surprises of 7.69% and 2.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for January 11th

by Zacks Equity Research

ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.

OptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 41.3% upside potential for OptimizeRx Corp. (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks.com featured highlights Freshpet, OptimizeRx and Pinterest

by Zacks Equity Research

Freshpet, OptimizeRx and Pinterest have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Stocks Worth a Buy for Superb Earnings Acceleration

by Tirthankar Chakraborty

Invest in stocks such as Freshpet (FRPT), OptimizeRx (OPRX) and Pinterest (PINS) at the moment for solid earnings acceleration.

Why OptimizeRx Corp. (OPRX) Might be Well Poised for a Surge

by Zacks Equity Research

OptimizeRx Corp. (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

How Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%

by Zacks Equity Research

The mean of analysts' price targets for OptimizeRx Corp. (OPRX) points to a 47.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptimizeRx Corp. (OPRX) Surges 13.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

OptimizeRx Corp. (OPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -12.50% and 5.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Soars 7.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates

by Zacks Equity Research

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 4.17% and 9.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sea Limited (SE) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Sea Limited's (SE) fourth-quarter 2022 results are likely to benefit from a stable Free Fire user base and the growing popularity of Shopee.

VMware (VMW) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

VMware (VMW) delivered earnings and revenue surprises of 7.58% and 2.16%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy OptimizeRx (OPRX) Ahead of Earnings?

by Zacks Equity Research

OptimizeRx (OPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Oracle (ORCL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Oracle (ORCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avid Technology (AVID) Q4 Earnings Lag Estimates

by Zacks Equity Research

Avid (AVID) delivered earnings and revenue surprises of -4.26% and 1.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in OptimizeRx Corp. (OPRX): Can Its 10.1% Jump Turn into More Strength?

by Zacks Equity Research

OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates

by Zacks Equity Research

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 75% and 0.47%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Commvault Systems (CVLT) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Commvault (CVLT) delivered earnings and revenue surprises of 14% and 0.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -60% and 18.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?